Skip to Content

Nivolumab monotherapy is an effective treatment option for recurrent malignant mesothelioma

The Phase 3 study CONFIRM presented at WCLC 2020 show that nivolumab monotherapy is an effective treatment option for recurrent malignant mesothelioma.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top